Table 2.
Internal responsiveness of HRQoL in improved and worsening patient groups
| HRQoL domains | Improveda (n = 16) | Worseninga (n = 34) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline mean (SD) | Follow-up mean (SD) | ES | SRM | p | Baseline mean (SD) | Follow-up mean (SD) | ES | SRM | p | |
| SF-36 | ||||||||||
| Physical functioning | 70.00 (25.36) | 78.13 (23.09) | 0.32 | 0.44 | 0.129 | 70.29 (23.39) | 63.97 (20.55) | −0.27 | −0.31 | 0.094 |
| Role-physical | 53.13 (46.44) | 56.25 (41.33) | 0.07 | 0.07 | 0.832 | 44.85 (40.26) | 39.71 (37.50) | −0.13 | −0.16 | 0.379 |
| Bodily pain | 74.25 (27.23) | 72.19 (24.85) | −0.08 | −0.15 | 0.611 | 73.44 (25.17) | 67.91 (26.22) | −0.22 | −0.26 | 0.061 |
| General health* | 51.75 (15.64) | 65.56 (20.03) | 0.88 | 0.65 | 0.017 | 52.41 (20.42) | 48.88 (21.14) | −0.17 | −0.19 | 0.271 |
| Mental health | 70.50 (19.09) | 73.00 (17.44) | 0.13 | 0.12 | 0.505 | 71.76 (23.88) | 68.12 (20.62) | −0.15 | −0.17 | 0.155 |
| Role-emotional | 60.42 (40.77) | 62.50 (29.50) | 0.05 | 0.05 | 0.888 | 58.82 (42.69) | 50.98 (41.22) | −0.18 | −0.19 | 0.388 |
| Social functioning† | 71.09 (29.13) | 80.47 (21.39) | 0.32 | 0.34 | 0.190 | 71.32 (24.72) | 61.76 (31.07) | −0.39 | −0.39 | 0.048 |
| Vitality† | 61.88 (20.89) | 61.56 (20.06) | −0.01 | −0.02 | 0.813 | 60.15 (23.73) | 52.35 (20.61) | −0.33 | −0.40 | 0.035 |
| Total scores† | 64.13 (22.65) | 68.71 (18.71) | 0.20 | 0.30 | 0.191 | 62.88 (21.54) | 56.71 (19.81) | −0.29 | −0.43 | 0.017 |
| PDQ-39 | ||||||||||
| Mobility** | 22.66 (24.60) | 14.69 (18.97) | 0.32 | 0.72 | 0.010 | 22.57 (23.82) | 29.2 (24.52) | −0.28 | −0.27 | 0.098 |
| ADL | 17.45 (18.77) | 12.76 (16.42) | 0.25 | 0.43 | 0.113 | 15.32 (16.69) | 18.26 (18.46) | −0.18 | −0.16 | 0.211 |
| Emotional well-being† | 10.68 (12.73) | 9.64 (16.30) | 0.08 | 0.12 | 0.159 | 18.14 (19.65) | 22.67 (18.55) | −0.23 | −0.26 | 0.035 |
| Stigma | 13.28 (18.38) | 7.81 (12.18) | 0.30 | 0.27 | 0.236 | 20.59 (22.64) | 23.53 (22.62) | −0.13 | −0.17 | 0.154 |
| Social support†† | 8.59 (16.28) | 7.03 (16.51) | 0.10 | 0.09 | 0.932 | 4.78 (8.59) | 15.07 (21.05) | −1.20 | −0.51 | 0.001 |
| Cognitions | 12.89 (14.34) | 16.02 (16.61) | −0.22 | −0.19 | 0.429 | 24.26 (20.46) | 29.41 (15.58) | −0.25 | −0.27 | 0.071 |
| Communication | 6.25 (9.86) | 10.94 (13.85) | −0.48 | −0.34 | 0.172 | 11.03 (19.43) | 20.59 (21.73) | −0.49 | −0.55 | 0.003 |
| Bodily discomfort† | 21.88 (20.16) | 14.06 (14.82) | 0.39 | 0.47 | 0.078 | 21.57 (20.73) | 27.45 (24.41) | −0.28 | −0.32 | 0.049 |
| SI†† | 14.21 (9.52) | 11.62 (11.72) | 0.27 | 0.37 | 0.074 | 17.28 (14.22) | 23.28 (14.58) | −0.42 | −0.55 | 0.004 |
SF-36 36-item Short Form Health Survey, PDQ-39 39-item Parkinson’s Disease Questionnaire Single Index, ADL activities of daily living, SI summary index, SD standard deviation, ES effect size, SRM standardized response mean
aThe minimal clinically important difference (MCID) of the Movement Disorder Society Revision of the Unified Parkinson’s Disease Rating Scale Part III was used to classify PD patients into improved and worsening groups
*Significant differences between baseline and follow-up in the improved group by using Wilcoxon test, *p < 0.05, **p < 0.01
†Significant differences between baseline and follow-up in the worsening group by using Wilcoxon test, † p < 0.05, †† p < 0.01